Compass Therapeutics (NASDAQ:CMPX) Rating Lowered to Hold at Lifesci Capital

Compass Therapeutics (NASDAQ:CMPX) was downgraded by equities researchers at Lifesci Capital from a “strong-buy” rating to a “hold” rating in a research note issued to investors on Tuesday, Zacks reports.

CMPX has been the subject of a number of other research reports. Wall Street Zen downgraded Compass Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 8th. Stifel Nicolaus set a $6.00 target price on Compass Therapeutics in a report on Monday, June 1st. Piper Sandler lifted their target price on Compass Therapeutics from $4.00 to $6.00 and gave the company an “overweight” rating in a research report on Friday, August 7th. Guggenheim decreased their price target on Compass Therapeutics to $4.00 and set a “buy” rating for the company in a report on Wednesday. Finally, LADENBURG THALM/SH SH initiated coverage on Compass Therapeutics in a research report on Wednesday, July 1st. They issued a “buy” rating and a $5.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $10.21.

Compass Therapeutics Trading Down 5.6%

CMPX opened at $1.17 on Tuesday. The company’s fifty day moving average price is $2.12 and its two-hundred day moving average price is $2.93. Compass Therapeutics has a 1-year low of $1.13 and a 1-year high of $6.88. The company has a market cap of $210.71 million, a price-to-earnings ratio of -2.92 and a beta of 0.95.

Compass Therapeutics (NASDAQ:CMPX) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02). As a group, equities analysts forecast that Compass Therapeutics will post -0.47 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of CMPX. BlackRock Inc. purchased a new stake in shares of Compass Therapeutics during the 2nd quarter valued at $24,707,000. Palo Alto Investors LP purchased a new position in shares of Compass Therapeutics in the 2nd quarter worth about $12,771,670. BVF Inc. IL grew its position in Compass Therapeutics by 63.5% during the fourth quarter. BVF Inc. IL now owns 7,764,842 shares of the company’s stock valued at $41,697,000 after buying an additional 3,014,842 shares during the period. Sofinnova Investments Inc. increased its holdings in Compass Therapeutics by 65.9% during the fourth quarter. Sofinnova Investments Inc. now owns 3,365,446 shares of the company’s stock worth $18,072,000 after buying an additional 1,336,560 shares during the last quarter. Finally, NEXTBio Capital Management LP purchased a new stake in Compass Therapeutics during the fourth quarter worth about $5,982,000. Hedge funds and other institutional investors own 68.43% of the company’s stock.

Key Stories Impacting Compass Therapeutics

Here are the key news stories impacting Compass Therapeutics this week:

• Positive Sentiment: Citizens JMP maintained a Market Outperform rating but lowered its price target to $4.00. The target implies substantial potential upside if Compass successfully addresses regulatory concerns and advances tovecimig toward approval.
• Positive Sentiment: Compass said it intends to continue pursuing the program despite the FDA feedback, signaling that management believes tovecimig remains commercially viable and that the additional regulatory requirements can be addressed. Compass vows to press on with FDA application despite new trial request
• Neutral Sentiment: Analysts and commentary described tovecimig as having a promising opportunity in biliary tract cancer, but warned that the development and regulatory window is becoming narrower, increasing execution risk. Compass Therapeutics: A Promising, But Shrinking, Window Of Opportunity
• Negative Sentiment: The FDA recommended that Compass conduct a trial demonstrating a survival benefit in previously treated, advanced biliary tract cancer before submitting a Biologics License Application. This could materially delay a potential filing, raise development costs and require additional financing. Compass Therapeutics Provides Regulatory Update on Tovecimig in Biliary Tract Cancer Following FDA Feedback
• Negative Sentiment: Wedbush downgraded CMPX from Outperform to Neutral and cut its price target to $1 from $5, citing the FDA’s additional-trial request and estimating further downside. LifeSci Capital also downgraded the stock to Hold. Wedbush Downgrades Compass Therapeutics

About Compass Therapeutics

Compass Therapeutics, Inc is a clinical-stage biotechnology company focused on developing antibody-based medicines designed to activate and direct the immune system against cancer and other serious diseases. The company’s research is centered on immuno-oncology, with the goal of creating therapies that can stimulate antitumor immune responses and improve outcomes for patients.

Compass Therapeutics has developed a pipeline of proprietary antibody therapeutics, including CTX-471, an investigational monoclonal antibody intended to activate CD137, an immune-stimulatory receptor found on certain immune cells.